Analysis and Debate of TRIPS Waiver

  • Drishti Arora
  • Show Author Details
  • Drishti Arora

    Student at OP Jindal Global University, India

  • img Save PDF


This paper analyzes and debates the TRIPS Waiver decision in the context of the COVID-19 pandemic, focusing on its implications for vaccine access and pharmaceutical innovation. It begins by examining the TRIPS Agreement and compulsory licensing mechanisms, highlighting their limitations in addressing global health inequalities. The proposal and eventual decision to waive certain intellectual property rights, particularly related to COVID-19 vaccines, are discussed, along with the debates surrounding this decision. Proponents argue for prioritizing public health and equitable access to medications, while opponents express concerns about the impact on innovation and quality control. The paper evaluates the TRIPS Waiver decision as a positive step but calls for its expansion to include diagnostics and therapeutics. It emphasizes the importance of addressing disparities in vaccine distribution and pharmaceutical access, advocating for coordinated global efforts to ensure fairness and resilience in healthcare systems. Ultimately, the paper underscores the need for a comprehensive approach that balances intellectual property rights with public health priorities.


Research Paper


International Journal of Legal Science and Innovation, Volume 6, Issue 3, Page 157 - 166


Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution -NonCommercial 4.0 International (CC BY-NC 4.0) (, which permits remixing, adapting, and building upon the work for non-commercial use, provided the original work is properly cited.


Copyright © IJLSI 2021